Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Treatment of uncomplicated gonococcal infections

INTRODUCTION

Gonococcal infections, including urethritis, cervicitis, epididymitis, and proctitis, are a significant cause of morbidity among sexually active men and women. The treatment of these sexually transmitted infections (STIs) has evolved over the years, mainly due to the emergence of antibiotic resistance.

Urogenital, anogenital, pharyngeal, and ocular gonococcal infections that are not associated with bacteremic or ascending spread of the pathogen to other organs are considered uncomplicated. This topic will address the treatment of these gonococcal infections, with a focus on urogenital infections. In 2012, the United States Centers for Disease Control and Prevention updated their guidelines on the treatment of Neisseria gonorrhoeae [1]. The information in this topic is largely consistent with those guidelines, as well as the 2010 sexually transmitted disease (STD) treatment guidelines [2].

The clinical manifestations and diagnosis of gonorrhea are discussed elsewhere. The treatment of complicated infections, such as disseminated gonococcal infection and pelvic inflammatory disease, is found elsewhere. (See "Epidemiology and pathogenesis of Neisseria gonorrhoeae infection" and "Cutaneous manifestations of gonorrhea" and "Clinical manifestations and diagnosis of Neisseria gonorrhoeae infection in adults and adolescents" and "Disseminated gonococcal infection" and "Treatment of pelvic inflammatory disease", section on 'Recommended regimens'.)

GENERAL BACKGROUND

Therapeutic principles — It is desirable for a therapeutic gonococcal regimen to:

Be highly effective at all anatomic sites of infection

                                            

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Oct 2014. | This topic last updated: Nov 6, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Centers for Disease Control and Prevention (CDC). Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 2012; 61:590.
  2. http://www.cdc.gov/std/treatment/2010/default.htm (Accessed on January 13, 2011).
  3. Workowski KA, Berman SM, Douglas JM Jr. Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies. Ann Intern Med 2008; 148:606.
  4. Newman LM, Moran JS, Workowski KA. Update on the management of gonorrhea in adults in the United States. Clin Infect Dis 2007; 44 Suppl 3:S84.
  5. Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis 1995; 20 Suppl 1:S47.
  6. Datta SD, Sternberg M, Johnson RE, et al. Gonorrhea and chlamydia in the United States among persons 14 to 39 years of age, 1999 to 2002. Ann Intern Med 2007; 147:89.
  7. Gottlieb SL, Berman SM, Low N. Screening and treatment to prevent sequelae in women with Chlamydia trachomatis genital infection: how much do we know? J Infect Dis 2010; 201 Suppl 2:S156.
  8. Ross JD, Lewis DA. Cephalosporin resistant Neisseria gonorrhoeae: time to consider gentamicin? Sex Transm Infect 2012; 88:6.
  9. European Centre for Disease Prevention and Control. Gonococcal antimicrobial susceptibility surveillance in Europe - 2010. ECDC, Stockholm, 2012.
  10. Australian Gonococcal Surveillance Programme annual reports. http://www.health.gov.au/internet/main/publishing.nsf/content/cda-pubs-annlrpt-gonoanrep.htm (Accessed on November 01, 2014).
  11. Centers for Disease Control and Prevention (CDC). Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep 2007; 56:332.
  12. Sparling PF. Antibiotic resistance in Neisseria gonorrhoeae. Med Clin North Am 1972; 56:1133.
  13. Kirkcaldy RD, Zaidi A, Hook EW 3rd, et al. Neisseria gonorrhoeae antimicrobial resistance among men who have sex with men and men who have sex exclusively with women: the Gonococcal Isolate Surveillance Project, 2005-2010. Ann Intern Med 2013; 158:321.
  14. Brown LB, Krysiak R, Kamanga G, et al. Neisseria gonorrhoeae antimicrobial susceptibility in Lilongwe, Malawi, 2007. Sex Transm Dis 2010; 37:169.
  15. Schwarcz SK, Zenilman JM, Schnell D, et al. National surveillance of antimicrobial resistance in Neisseria gonorrhoeae. The Gonococcal Isolate Surveillance Project. JAMA 1990; 264:1413.
  16. Centers for Disease Control and Prevention (CDC). Cephalosporin susceptibility among Neisseria gonorrhoeae isolates--United States, 2000-2010. MMWR Morb Mortal Wkly Rep 2011; 60:873.
  17. Muratani T, Akasaka S, Kobayashi T, et al. Outbreak of cefozopran (penicillin, oral cephems, and aztreonam)-resistant Neisseria gonorrhoeae in Japan. Antimicrob Agents Chemother 2001; 45:3603.
  18. Yokoi S, Deguchi T, Ozawa T, et al. Threat to cefixime treatment for gonorrhea. Emerg Infect Dis 2007; 13:1275.
  19. Barry PM, Klausner JD. The use of cephalosporins for gonorrhea: the impending problem of resistance. Expert Opin Pharmacother 2009; 10:555.
  20. Allen VG, Mitterni L, Seah C, et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA 2013; 309:163.
  21. Chisholm SA, Mouton JW, Lewis DA, et al. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? J Antimicrob Chemother 2010; 65:2141.
  22. Martin I, Sawatzky P, Allen V, et al. Emergence and characterization of Neisseria gonorrhoeae isolates with decreased susceptibilities to ceftriaxone and cefixime in Canada: 2001-2010. Sex Transm Dis 2012; 39:316.
  23. Ray K, Bala M, Kumari S, Narain JP. Antimicrobial resistance of Neisseria gonorrhoeae in selected World Health Organization Southeast Asia Region countries: an overview. Sex Transm Dis 2005; 32:178.
  24. Starnino S, GASP-LAC Working Group, Galarza P, et al. Retrospective analysis of antimicrobial susceptibility trends (2000-2009) in Neisseria gonorrhoeae isolates from countries in Latin America and the Caribbean shows evolving resistance to ciprofloxacin, azithromycin and decreased susceptibility to ceftriaxone. Sex Transm Dis 2012; 39:813.
  25. Lahra MM, Ryder N, Whiley DM. A new multidrug-resistant strain of Neisseria gonorrhoeae in Australia. N Engl J Med 2014; 371:1850.
  26. Ohnishi M, Golparian D, Shimuta K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011; 55:3538.
  27. Ohnishi M, Saika T, Hoshina S, et al. Ceftriaxone-resistant Neisseria gonorrhoeae, Japan. Emerg Infect Dis 2011; 17:148.
  28. Unemo M, Golparian D, Nicholas R, et al. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012; 56:1273.
  29. Unemo M, Golparian D, Hestner A. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill 2011; 16.
  30. Bolan GA, Sparling PF, Wasserheit JN. The emerging threat of untreatable gonococcal infection. N Engl J Med 2012; 366:485.
  31. Whiley DM, Goire N, Lahra MM, et al. The ticking time bomb: escalating antibiotic resistance in Neisseria gonorrhoeae is a public health disaster in waiting. J Antimicrob Chemother 2012; 67:2059.
  32. Centers for Disease Control and Prevention (CDC). Sexually Transmitted Disease Surveillance, 2008. CDC; Department of Health and Human Services, Atlanta, GA 2009.
  33. Centers for Disease Control and Prevention (CDC). Neisseria gonorrhoeae with reduced susceptibility to azithromycin--San Diego County, California, 2009. MMWR Morb Mortal Wkly Rep 2011; 60:579.
  34. Katz AR, Komeya AY, Soge OO, et al. Neisseria gonorrhoeae with high-level resistance to azithromycin: case report of the first isolate identified in the United States. Clin Infect Dis 2012; 54:841.
  35. Yuan LF, Yin YP, Dai XQ, et al. Resistance to azithromycin of Neisseria gonorrhoeae isolates from 2 cities in China. Sex Transm Dis 2011; 38:764.
  36. Lo JY, Ho KM, Lo AC. Surveillance of gonococcal antimicrobial susceptibility resulting in early detection of emerging resistance. J Antimicrob Chemother 2012; 67:1422.
  37. Centers for Disease Control and Prevention. 2010 Sexually transmitted diseases surveillance - Gonorrhea. http://www.cdc.gov/std/stats10/gonorrhea.htm (Accessed on June 13, 2012).
  38. Cole MJ, Chisholm SA, Hoffmann S, et al. European surveillance of antimicrobial resistance in Neisseria gonorrhoeae. Sex Transm Infect 2010; 86:427.
  39. Boslego JW, Tramont EC, Takafuji ET, et al. Effect of spectinomycin use on the prevalence of spectinomycin-resistant and of penicillinase-producing Neisseria gonorrhoeae. N Engl J Med 1987; 317:272.
  40. Kunz AN, Begum AA, Wu H, et al. Impact of fluoroquinolone resistance mutations on gonococcal fitness and in vivo selection for compensatory mutations. J Infect Dis 2012; 205:1821.
  41. Dillon JA, Parti RP. Fluoroquinolone resistance in Neisseria gonorrhoeae: fitness cost or benefit? J Infect Dis 2012; 205:1775.
  42. Cohen MS. Sexually transmitted diseases enhance HIV transmission: no longer a hypothesis. Lancet 1998; 351 Suppl 3:5.
  43. Wang SA, Harvey AB, Conner SM, et al. Antimicrobial resistance for Neisseria gonorrhoeae in the United States, 1988 to 2003: the spread of fluoroquinolone resistance. Ann Intern Med 2007; 147:81.
  44. British Association for Sexual Health and HIV. BASHH Clinical Effectiveness Group Guidelines. http://www.bashh.org/guidelines (Accessed on June 13, 2012).
  45. Bai ZG, Bao XJ, Cheng WD, et al. Efficacy and safety of ceftriaxone for uncomplicated gonorrhoea: a meta-analysis of randomized controlled trials. Int J STD AIDS 2012; 23:126.
  46. Moran JS. Treating uncomplicated Neisseria gonorrhoeae infections: is the anatomic site of infection important? Sex Transm Dis 1995; 22:39.
  47. Handsfield HH, McCormack WM, Hook EW 3rd, et al. A comparison of single-dose cefixime with ceftriaxone as treatment for uncomplicated gonorrhea. The Gonorrhea Treatment Study Group. N Engl J Med 1991; 325:1337.
  48. Ison CA, Mouton JW, Jones K, et al. Which cephalosporin for gonorrhoea? Sex Transm Infect 2004; 80:386.
  49. Pandori M, Barry PM, Wu A, et al. Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California. Antimicrob Agents Chemother 2009; 53:4032.
  50. Centers for Disease Control and Prevention (CDC). Gonococcal Isolate Surveillance Project (GISP) annual report — 2004. CDC; Department of Health and Human Services, Atlanta, GA 2005.
  51. Bignell C, Garley J. Azithromycin in the treatment of infection with Neisseria gonorrhoeae. Sex Transm Infect 2010; 86:422.
  52. Handsfield HH, Dalu ZA, Martin DH, et al. Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea. Azithromycin Gonorrhea Study Group. Sex Transm Dis 1994; 21:107.
  53. Centers for Disease Control and Prevention. Notice to readers: Discontinuation of spectinomycin. MMWR Morb Mortal Wkly Rep 2006; 55:370.
  54. Kirkcaldy RD, Weinstock HS, Moore PC, et al. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin Infect Dis 2014; 59:1083.
  55. Weinstock H, Workowski KA. Pharyngeal gonorrhea: an important reservoir of infection? Clin Infect Dis 2009; 49:1798.
  56. Barbee LA, Kerani RP, Dombrowski JC, et al. A retrospective comparative study of 2-drug oral and intramuscular cephalosporin treatment regimens for pharyngeal gonorrhea. Clin Infect Dis 2013; 56:1539.
  57. Haimovici R, Roussel TJ. Treatment of gonococcal conjunctivitis with single-dose intramuscular ceftriaxone. Am J Ophthalmol 1989; 107:511.
  58. Trojian TH, Lishnak TS, Heiman D. Epididymitis and orchitis: an overview. Am Fam Physician 2009; 79:583.
  59. Haizlip J, Isbey SF, Hamilton HA, et al. Time required for elimination of Neisseria gonorrhoeae from the urogenital tract in men with symptomatic urethritis: comparison of oral and intramuscular single-dose therapy. Sex Transm Dis 1995; 22:145.
  60. Schwarcz S, Weinstock H, Louie B, et al. Characteristics of persons with recently acquired HIV infection: application of the serologic testing algorithm for recent HIV seroconversion in 10 US cities. J Acquir Immune Defic Syndr 2007; 44:112.
  61. CDC Dear Colleague letter regarding azithromycin resistance in N. gonorrhoeae. http://www.cdc.gov/std/gonorrhea/DCL-Azithro-GC-May-24-2011.pdf (Accessed on June 19, 2012).
  62. Yokoi S, Maeda S, Kubota Y, et al. The role of Mycoplasma genitalium and Ureaplasma urealyticum biovar 2 in postgonococcal urethritis. Clin Infect Dis 2007; 45:866.
  63. Mobley VL, Hobbs MM, Lau K, et al. Mycoplasma genitalium infection in women attending a sexually transmitted infection clinic: diagnostic specimen type, coinfections, and predictors. Sex Transm Dis 2012; 39:706.
  64. Hamasuna R, Osada Y, Jensen JS. Antibiotic susceptibility testing of Mycoplasma genitalium by TaqMan 5' nuclease real-time PCR. Antimicrob Agents Chemother 2005; 49:4993.
  65. Mena LA, Mroczkowski TF, Nsuami M, Martin DH. A randomized comparison of azithromycin and doxycycline for the treatment of Mycoplasma genitalium-positive urethritis in men. Clin Infect Dis 2009; 48:1649.
  66. Schwebke JR, Rompalo A, Taylor S, et al. Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens--a randomized clinical trial. Clin Infect Dis 2011; 52:163.
  67. Bradshaw CS, Chen MY, Fairley CK. Persistence of Mycoplasma genitalium following azithromycin therapy. PLoS One 2008; 3:e3618.
  68. Björnelius E, Anagrius C, Bojs G, et al. Antibiotic treatment of symptomatic Mycoplasma genitalium infection in Scandinavia: a controlled clinical trial. Sex Transm Infect 2008; 84:72.
  69. Erbelding EJ, Zenilman JM. Toward better control of sexually transmitted diseases. N Engl J Med 2005; 352:720.
  70. Golden MR. Expedited partner therapy for sexually transmitted diseases. Clin Infect Dis 2005; 41:630.
  71. Golden MR, Whittington WL, Handsfield HH, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005; 352:676.
  72. Kissinger P, Mohammed H, Richardson-Alston G, et al. Patient-delivered partner treatment for male urethritis: a randomized, controlled trial. Clin Infect Dis 2005; 41:623.
  73. http://www.cdc.gov/std/ept/gc-guidance.htm (Accessed on October 21, 2014).